Quick answer
What does high purity mean for IGF-1 LR3? IGF-1 LR3 is an 83-residue analog of IGF-I with Arg at position 3 and an N-terminal extension. It has three disulfide bonds, so correctly and incorrectly folded forms can share a mass. High purity needs a dominant HPLC peak, an intact mass consistent with the page formula C400H625N111O115S9 (about 9,117.6 g/mol average), and ideally relative bioactivity versus native IGF-I.
A search for a high-purity IGF-1 LR3 source is a search for assurance, and for a folded protein of about 9 kDa the assurance has to come from several checks, not one number. This article derives those checks from the product page and the primary literature, so any lot from any source can be evaluated the same way. For laboratory research use only; not for human consumption.
What the product page lists, and what it leaves open
The IGF-1 LR3 product page describes Long-arginine-3 IGF-1, an analog of insulin-like growth factor 1, supplied as a 1 mg lyophilized powder with purity stated as ≥98% by HPLC. It gives a molecular formula, C400H625N111O115S9, and describes the molecule as an 83-amino-acid analog; the sequence line says it is reported on the certificate of analysis where published, and at the time this article was written the page showed the certificate as in progress. Storage is at 2–8 °C with −20 °C for the long term, protected from heat, moisture and light. The page lists IGF-1 receptor signaling, cell-proliferation and culture research and anabolic-pathway models as research applications.
That combination, a formula but no published sequence or certificate, is exactly the situation in which a buyer's own verification matters most. This article is about what "high purity" has to mean for a protein of about 9 kDa with three disulfide bonds, which is a different problem from a 3 kDa linear peptide. It is not a buying recommendation: it is a checklist that a laboratory can apply to any lot of this analog from any source. Companion library pages cover the compound overview and purity testing.
The molecule: what 83 residues means
Native IGF-I has 70 amino acids. The LR3 analog, as constructed in the original work, is a fusion-derived analog: an N-terminal extension of the first 11 residues of methionyl porcine growth hormone plus a Val-Asn dipeptide (13 residues in all, giving 83 residues with the 70 of IGF-I), with Glu at position 3 of the IGF-I sequence replaced by Arg. The three analogs in that work were called Long IGF-I, Long [Gly3]-IGF-I and Long [Arg3]-IGF-I, depending on the IGF-I sequence present [1]. A related expression system used a longer fusion, the first 46 amino acids of methionyl porcine GH followed by Val-Asn, with a hydroxylamine-sensitive Asn-Gly link that allows the extension to be cleaved, and produced IGF-I, [Gly3]-IGF-I and [Arg3]-IGF-I whose purity was established by HPLC and N-terminal sequence analysis [2].
| Feature | Value or description | Why it matters for verification |
|---|---|---|
| Total length | 83 residues (product page) | Mass spectrometry should reflect an 83-residue protein, not native 70-residue IGF-I |
| N-terminal extension | 13 residues (Met plus pGH residues 2-11, then Val-Asn) in the original construct [1] | Defines the intact mass and the N-terminal sequence |
| Position 3 | Arg instead of Glu [1] | Reduces binding to IGF-binding proteins, the basis of its higher potency in cell lines that secrete them [1][2] |
| Disulfide bonds | Three, as in native IGF-I [3] | Folding determines activity; mispaired forms share the mass |
| Formula | C400H625N111O115S9 (product page) | Calculated average mass about 9,117.6 g/mol; monoisotopic about 9,111.4 Da |
| Sulfur atoms | Nine | Six cysteines (three disulfides) plus three methionines are the sulfur-containing residues; useful for sanity checks |
The mass figures are arithmetic from the page formula and standard atomic masses; a measured value should be compared with them, and with the sequence reported on the certificate, within the instrument's stated accuracy. The gap between average and monoisotopic mass for a species this large is about 6 Da, and an intact-protein spectrum is normally reported as a deconvoluted average mass rather than as a single isotopic peak.
Why folding is the central purity problem
For a linear peptide, the chief purity risks are deletions and truncations. For IGF-I and its analogs the dominant risk is different: the three disulfide bonds can pair incorrectly. Hober and colleagues reported that IGF-I does not quantitatively form its three native disulfide bonds in the presence of 10 mM reduced and 1 mM oxidized glutathione in vitro, and that IGF-I and IGF-II were unable to form and maintain their native disulfides at redox conditions similar to the secretory vesicles in vivo, with protein disulfide isomerase not overcoming the problem. They described this as a thermodynamic disulfide-exchange folding problem and speculated that it is biologically significant for generating variants destined for rapid clearance [3]. The original expression work addressed folding directly: production of the purified fusion peptides was aided by folding the reduced and denatured fusion peptide under conditions that gave very high yields of biologically active product [1].
The consequence for quality is that a lot can contain mispaired disulfide isoforms that have the same mass as the correct protein. They elute at different positions on reverse-phase HPLC, which is why an HPLC trace with a single dominant peak is meaningful, and why a trace with a broad or shouldered main peak deserves a question. Isoforms of different pairing may differ sharply in receptor binding and activity, which makes bioactivity the check that mass cannot replace.
| Impurity or variant | Mass relative to target | Seen by | Comment |
|---|---|---|---|
| Mispaired disulfide isoform | Same | RP-HPLC (shifted retention); non-reducing peptide mapping | Cannot be seen by intact mass alone |
| Reduced form (one or more free thiols) | +2 Da per disulfide opened | Intact LC-MS; Ellman assay for free thiols | Indicates incomplete oxidation |
| Methionine oxidation | +16 Da per oxidized Met | Intact or peptide-mapping LC-MS | Three methionines in the formula as listed |
| Deamidation | +0.984 Da | High-resolution MS; ion-exchange HPLC | Slow; accumulates in solution [4] |
| Truncated or extended N-terminus | Varies | LC-MS; N-terminal sequencing | The N-terminal extension is the defining feature [1] |
| Aggregates | Non-covalent; invisible to MS | Size-exclusion HPLC | Increased by freeze-thaw and surface exposure [5] |
| Host-cell proteins, endotoxin | Not seen in HPLC of the main product | Specific assays | Common contaminants of recombinant proteins [6] |
Bioactivity: the check that mass cannot replace
Because correctly and incorrectly folded forms share a mass, a functional readout is the strongest confirmation of identity and folding. The original characterization shows what such a readout looks like and how it depends on the cell system. In rat L6 myoblasts, [Gly3]-IGF-I and [Arg3]-IGF-I were more potent than IGF-I in assays of protein synthesis, DNA synthesis and inhibition of protein breakdown, and both bound very poorly to bovine IGF-binding protein-2 and slightly less well than IGF-I to the type-1 receptor; the authors concluded that reduced binding to IGF-binding proteins, not increased receptor binding, is the likely explanation for the higher potency [2]. The follow-up work with the Long analogs found that the order of potency in cell lines secreting IGF-binding proteins was Long [Arg3]-IGF-I-des(1-3)IGF-I greater than Long [Gly3]-IGF-I greater than Long IGF-I greater than IGF-I, whereas in chicken embryo fibroblasts, which do not secrete detectable binding proteins, Long [Arg3]-IGF-I was less potent than IGF-I; in H35 hepatoma cells, where the IGFs act through the insulin receptor, the Long analogs kept a similar potency relative to IGF-I as in myoblasts [1].
Two design rules follow. First, a bioassay for an LR3 lot should run native IGF-I alongside as a reference, because the meaningful quantity is relative potency, not an absolute value. Second, the cell system must be chosen with the binding-protein question in mind: the same lot will look more potent than IGF-I in a binding-protein-secreting line and less potent in one that does not secrete them [1]. That cell-system dependence is also the central theme of the library article on serum-free culture and binding proteins.
| Readout | What it confirms | Reference cell systems in the literature |
|---|---|---|
| Protein synthesis or DNA synthesis stimulation | Functional activity of the analog relative to IGF-I | Rat L6 myoblasts [2] |
| Receptor binding competition | Type-1 receptor affinity (slightly lower than IGF-I for the Gly3 and Arg3 analogs) | Rat L6 myoblasts [2] |
| Binding-protein interaction | Poor binding to IGFBP-2 for the Gly3 and Arg3 analogs | Bovine IGFBP-2 [2] |
| Insulin-receptor-mediated response | Potency relative to IGF-I preserved in cells where IGFs act through the insulin receptor | H35 hepatoma cells [1] |
| No-binding-protein control | Potency relative to IGF-I lower for Long [Arg3]-IGF-I | Chicken embryo fibroblasts [1] |
A verification worksheet for an 83-residue analog
| Check | Expected | If it fails |
|---|---|---|
| Intact mass by LC-MS | Deconvoluted average mass consistent with the formula-derived ≈9,117.6 g/mol, within instrument accuracy | Query the supplier; do not proceed to bioassay |
| HPLC trace | One dominant, symmetric main peak; method, column and gradient stated | Broad or shouldered peak suggests isoforms |
| Sequence confirmation | N-terminal sequence or peptide-mapping coverage reported | Request it; the page states the sequence is reported on the certificate where published |
| Disulfide integrity | Non-reducing versus reducing comparison, or free-thiol assay | Note as an uncharacterized risk |
| Relative bioactivity | Potency versus native IGF-I in a defined cell system [1][2] | Hold the lot |
| Endotoxin | Level reported if cells are sensitive to it [6] | Add an endotoxin test or a polymyxin control |
| Lot, date, counterion, net content | All present on the certificate | Record the gaps |
On the published-certificate point: the product page presently shows the certificate as in progress, so a buyer should not assume that any of these fields has been documented for that lot until the certificate is posted. The COA library lists what is published, and how to read a COA, HPLC versus mass spectrometry and understanding HPLC purity explain each field. Vendor-neutral questions to put to any source are listed in red flags when buying research peptides and how to buy research peptides online.
Handling after receipt
Storage and reconstitution can undo verified quality. The stability reviews describe oxidation, deamidation, aggregation, adsorption and freeze-thaw damage as the main risks for protein pharmaceuticals [4][5][7]; for IGF-I analogs, surface adsorption at low concentrations is a practical concern, and the labware literature shows that the choice of tube changes recovery of peptides [8]. Store as the product page states, refrigerated or frozen, protected from heat, moisture and light; reconstitute only what the experiment needs; and prepare single-use aliquots if freezing. How to reconstitute IGF-1 LR3 for lab work and the storage and stability guide give the steps, and the calculator applies the dilution arithmetic from label mass and diluent volume. The related analog is compared in LR3 versus des(1-3) IGF-1, and the shop lists the catalog.
All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.
Frequently asked questions
What does high purity mean for IGF-1 LR3?
A dominant HPLC main peak with the method stated, an intact mass consistent with the formula, evidence of correct folding and, ideally, relative bioactivity versus native IGF-I. A percentage alone does not cover folding.
What formula does the product page list?
C400H625N111O115S9, an 83-amino-acid analog, with a calculated average mass of about 9,117.6 g/mol.
Why does folding matter more for IGF-1 LR3 than for a short peptide?
It has three disulfide bonds, and IGF-I does not quantitatively form its native bonds under some redox conditions, so mispaired forms with the same mass are a real risk.
Can mass spectrometry detect a mispaired disulfide isoform?
Not from the intact mass, because the isoform has the same mass. Retention shifts on HPLC and non-reducing peptide mapping are the tools.
What does Arg3 do?
In the original work the Gly3 and Arg3 analogs bound very poorly to IGF-binding protein-2 and were more potent than IGF-I in binding-protein-secreting systems.
Is LR3 always more potent than IGF-I?
No. In chicken embryo fibroblasts, which do not secrete detectable binding proteins, Long [Arg3]-IGF-I was less potent than IGF-I.
What is the status of the certificate on the product page?
The page showed the certificate as in progress when this article was written; check the COA library for current status.
Why run native IGF-I alongside a bioassay?
Relative potency is the meaningful number, and absolute values vary with cell system and binding-protein content.
How should I store the vial?
As the product page states: refrigerated at 2–8 °C, or at −20 °C for the long term, protected from heat, moisture and light.
Related reading: What Is IGF-1 LR3? A Plain-Language Research Guide.
References
- Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-23. doi:10.1677/jme.0.0080213
- King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, et al. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. J Mol Endocrinol. 1992;8(1):29-41. doi:10.1677/jme.0.0080029
- Hober S, Lundström Ljung J, Uhlén M, Nilsson B. Insulin-like growth factors I and II are unable to form and maintain their native disulfides under in vivo redox conditions. FEBS Lett. 1999;443(3):271-6. doi:10.1016/s0014-5793(98)01737-2
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-794. PMID: 3805008
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A Jr. Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci. 2007;10(3):388-404. PMID: 17727802
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
